Alpha Teknova, Inc.

Good day and thank you for standing by. Welcome to the Technova 3rd Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to your first speaker today, Sarah Mitchell-Morse. Thank you. Please go ahead.

Thank you, Operator. Welcome to Technova's third quarter 2021 earnings conference call. On today's call, Stephen Gunstream, Technova's Chief Executive Officer, will provide business highlights and updates, followed by Matt Lowell, Technova's Chief Financial Officer, who will review financial results. After we conclude the prepared remarks, we will be happy to take your questions. As a reminder, the forward-looking statements that we make during this call, including those regarding business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning these risk factors is included in the press release the company issued earlier today and are more fully described in the company's various filings with the SEC. Today's comments reflect the company's current views which could change as a result of new information, future events, or other factors, and the company does not obligate or commit itself to update these forward-looking statements except as required by law. The company's management believes that in addition to GAAP results, non-GAAP financial measures can provide meaningful insight when evaluating the company's financial performance and the effectiveness of its business strategies. During this call, we will therefore use non-GAAP financial measures of certain of our results Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this afternoon, which is posted to Technova's website and at www.sec.gov/.edgar. Non-GAAP financial measures should always be considered only as a supplement to and not as a substitute for financial measures prepared in accordance with GAAP. The non-GAAP financial measures in this presentation may differ from similarly named non-GAAP financial measures used by other companies. Please be advised the company has posted a supplemental slide deck to accompany today's prepared remark on its website, and that can be accessed through the investor relations section of Technova's website and on today's webcast. And with that, I'll turn the call over to Stephen.

Thank you, Sarah. Good afternoon and thank you everyone for joining us for our third quarter earnings call. Technova is a leading provider of critical reagents that supports the discovery, development, and production of drug therapies, novel vaccines, and molecular diagnostics. We manufacture high quality customer agents with short turnaround times and are able to scale with our customers from discovery to commercialization. To give you an example, In cell and gene therapy, there is significant need for custom-made reagents in volumes smaller than 1,000 liters. Our short turnaround of custom clinical-grade bioprocessing solutions enabled our cell and gene therapy customers to reduce the time from drug discovery to clinical impact. Over the last several months, I and other members of our team have participated in various industry conferences and events and met with a number of customers and high potential prospects. I've been energized by these interactions, particularly in the cell and gene therapy space. We believe there is market demand for high-quality custom solutions. Our discussions have validated our thinking and strongly reinforced to me that our capabilities, including our quick turnaround, meet the critical need in the industry supply chain. We are well-positioned to benefit over time, one, as our customers advance their products or therapies through their clinical development pipelines, and two, from growth in the broader market segments. We have the infrastructure in place today to support our near-term outlook. Our balance sheet is strong, and we are making good progress in positioning the company for long-term growth by investing in capacity expansion, commercial excellence, and R&D. Lastly, we have the team in place to execute on our vision. I want to thank all of our 215-plus associates whose dedication has been and will continue to be critical to our success. Moving to our business update, I'm pleased to report that in the third quarter we performed well commercially and made meaningful progress on our investment priorities. First, our total Q3 revenue excluding sample transport media was $9.3 million, up 26% as compared to $7.4 million in the third quarter of 2020. Second, we advanced construction on our new state-of-the-art GMP manufacturing facility in Hollister, California, which, when operational at the end of 2022, will increase production capacity by fivefold. We also made efficiency and capacity improvements at our existing facilities. Third, we continued to invest in talented areas that are critical to our near and long-term success. For example, in the third quarter, we expanded our R&D process engineering and automation teams to support the new manufacturing facility build-out. Finally, today we announced that we expanded our leadership team with two key hires in our commercial organization. I want to formally welcome Ken Gelhaus, who will serve as Chief Commercial Officer, and Jen Henry, who is joining the company as our Senior Vice President of Marketing. Ken will lead sales, product management, commercial operations, and customer service at Technova. Ken has significant experience in the commercial roles at life science companies, most recently at Beckton Dickinson, where he was responsible for the global clinical solutions business unit of BD Biosciences. Ken and I worked together at BD, and his background in building commercial organizations and leading complex businesses makes him an ideal fit for the role. Jen comes to Technova from the technology industry, with past roles in marketing at eBay, Facebook, Google, and Apple. Hiring outside of the life sciences for this role was intentional on our part. We wanted a top marketing talent, of course, but also someone who would bring fresh perspective and creative thinking to our customers. Jen is a brand specialist of the highest order, has led some of the biggest launches in the tech industry, including the original iPhone, and has proven to be adept at adjusting to new environments and building teams. I'm thrilled to have both Ken and Jen join the Technova team, and I look forward to them contributing to our future success. Overall, we are encouraged by our third quarter performance and excited with the progress we've made against our strategic plan. Looking through the remainder of the year, our priorities remain consistent, and we will continue to be laser-focused on execution and laying the foundation to support our long-term growth opportunities. I will now hand the call over to Matt for a discussion of the financials.